'Little guys' fight Genzyme buyout
Investors: Bioenvision deal is 'sham,' catering to Soros
Angry at what they say is an unfairly priced takeover attempt by Genzyme Corp. , more than three dozen small shareholders of a New York biotechnology firm are trying to band together to block Genzyme's deal to buy the company. (Full article: 1002 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
